Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on October 6, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, and Chairman of IRADIMED CORP (IRMD), reported the sale of 5,000 shares of common stock.
• The transactions occurred on October 6, 2025.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• A total of 4,800 shares were sold at a weighted average price of $71.7 per share, with prices ranging from $71.25 to $72.21.
• An additional 200 shares were sold at a price of $72.27 per share.
• Following these transactions, Susi's indirect beneficial ownership through the Phillip Susi 2008 Dynasty Trust decreased to 2,342,500 shares.
• Susi also indirectly beneficially owns 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, disclaiming beneficial ownership of these except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sale of shares by the CEO is a routine insider transaction conducted under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling. The amount sold is relatively small compared to the CEO's total beneficial ownership, suggesting no significant change in confidence.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were scheduled in advance and not based on recent material non-public information. This enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

Not applicable. This filing does not provide forward-looking statements or guidance on company performance.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitor analysis.

Corporate Governance

Related Party Transactions

• The indirect beneficial ownership through the Phillip Susi 2008 Dynasty Trust, Roger E. Susi Revocable Trust, and Matthew Susi 2008 Dynasty Trust represents holdings by related parties, though the reported transaction is a direct sale by Roger E. Susi.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan provides transparency. The impact is likely minimal given the transaction's nature and size.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction report.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider sale by the CEO. The transaction is not indicative of new material information or a significant shift in the company's fundamentals. Investors should consider this a standard disclosure and not a signal for a change in investment thesis. The 10b5-1 plan provides transparency, making it a neutral event for the stock's valuation.

Keywords

IRADIMED CORP, IRMD, Roger E. Susi, Form 4, insider trading, stock sale, Rule 10b5-1 plan, CEO, beneficial ownership